Better at identifying who genuinely needs treatment — and who can safely avoid it.
For generations, the decision to prescribe blood pressure medication has rested on blunt thresholds rather than the full texture of a patient's life. A new scientific statement from the American Heart Association and American College of Cardiology, published August 29, 2025, changes that calculus by endorsing the PREVENT™ equations — a risk tool built on data from over six million diverse Americans — as the preferred method for guiding antihypertensive treatment decisions. The equations weave together kidney function, metabolic health, social deprivation, and more into a single risk portrait, asking not merely whether a number is high, but whether this particular person, in this particular life, truly needs a pill.
- Millions of Americans with stage 1 hypertension have long faced a binary choice — medicate or don't — made with tools too blunt to reflect their actual risk.
- The new PREVENT™ equations, endorsed by the AHA and ACC in a statement published simultaneously across three major journals, introduce a 7.5% ten-year CVD risk threshold as the clinical line separating lifestyle-only management from medication.
- A key fear — that the new threshold would quietly shrink the population eligible for treatment, leaving high-risk patients behind — has been directly addressed: the total number qualifying for medication remains comparable to the 2017 guideline, but the sorting is sharper.
- The tool's real power lies in what it combines: blood pressure, kidney function, metabolic markers, BMI, diabetes status, and even a zip code-based social deprivation index, making it the first cardiovascular risk calculator to unify heart, kidney, and metabolic health in a single primary-prevention score.
- The most immediate obstacle to impact is infrastructure — PREVENT™ must be embedded into electronic health record systems before personalized risk scoring can become routine rather than exceptional.
For millions of Americans with elevated blood pressure, the question of whether to start medication has long been answered with a blunt instrument. A new scientific statement from the American Heart Association and American College of Cardiology, published August 29, 2025, in Circulation, Hypertension, and JACC, makes the case for a sharper one — endorsing the PREVENT™ equations as the preferred tool for estimating cardiovascular risk in adults with high blood pressure.
Developed by the AHA in 2023 and built on data from more than six million diverse American adults, PREVENT™ can project 10-year and 30-year CVD risk for people aged 30 to 79 with no prior cardiovascular history. Unlike its predecessor, the Pooled Cohort Equations, which measured only atherosclerotic risk, PREVENT™ incorporates body mass index, kidney function, metabolic markers, diabetes status, and even a zip code-based social deprivation index — producing a risk portrait that reflects the full complexity of a patient's circumstances.
The stakes are most concrete for those with stage 1 hypertension. Under the accompanying 2025 AHA/ACC High Blood Pressure Guideline, patients whose PREVENT™-calculated 10-year CVD risk reaches or exceeds 7.5 percent should begin antihypertensive medication alongside lifestyle changes. Below that threshold, lifestyle modification alone may suffice.
One concern during the guideline's development was whether the new threshold would quietly reduce the number of patients recommended for medication. The scientific statement addresses this directly: the total population qualifying for treatment under the 2025 guideline is comparable to that under the 2017 guideline. The difference lies not in headcount but in precision — PREVENT™ is better at identifying who genuinely needs treatment and who can safely avoid it.
Sadiya S. Khan, chair of the scientific statement writing group, described PREVENT™ as the first risk instrument to combine cardiovascular, kidney, and metabolic health data in a single calculation aimed at primary prevention. The goal, she emphasized, is not merely to quantify risk but to act on it — and crucially, the risk posed by high blood pressure is not fixed. It can be changed.
For clinicians, the next challenge is practical: embedding the PREVENT™ calculator into electronic health record systems so that personalized risk scoring becomes a routine part of every hypertension visit. How quickly that infrastructure takes hold will likely determine how soon the guideline's promise translates into changed outcomes at the bedside.
For millions of Americans living with elevated blood pressure, the question of whether to start medication has long been answered with a blunt instrument. Now, a new scientific statement from the American Heart Association and the American College of Cardiology is making the case for a sharper one.
The statement, published simultaneously in Circulation, Hypertension, and JACC on August 29, 2025, endorses the use of the PREVENT™ equations — a risk-calculation tool the AHA developed in 2023 — as the preferred method for estimating cardiovascular disease risk in adults with high blood pressure. It arrives as a companion document to the newly released 2025 AHA/ACC High Blood Pressure Guideline, which formally recommends PREVENT™ for personalizing treatment decisions.
The equations themselves are built on data from more than six million diverse American adults and can project both 10-year and 30-year risk for total cardiovascular disease, including atherosclerotic cardiovascular disease and heart failure, in people between the ages of 30 and 79 who have no prior CVD history. What sets PREVENT™ apart from its predecessor — the Pooled Cohort Equations, which estimated only atherosclerotic risk — is the breadth of what it measures. The calculator incorporates body mass index, blood pressure readings, diabetes status, kidney function, metabolic health markers, and even a zip code-based social deprivation index. The result is a risk portrait that reflects the full complexity of a patient's life, not just their cholesterol numbers.
The practical stakes are clearest for people with stage 1 hypertension — defined as a systolic blood pressure between 130 and 139 mm Hg, or a diastolic reading between 80 and 89 mm Hg. Under the 2025 guideline, those patients should begin antihypertensive medication alongside lifestyle changes if their PREVENT™-calculated 10-year CVD risk reaches or exceeds 7.5 percent. That threshold is a meaningful clinical line: below it, lifestyle modification alone may suffice; above it, the evidence supports adding a pill.
One concern that shadowed the guideline's development was whether the new risk threshold would effectively shrink the pool of patients recommended for medication — leaving some high-risk individuals untreated. The scientific statement addresses this directly. The total number of people who qualify for antihypertensive therapy under the 2025 guideline is comparable to the number under the 2017 guideline. The difference is not in the headcount but in the accuracy of the sorting: PREVENT™ is better at identifying who genuinely needs treatment and who can safely avoid it.
Daniel W. Jones, dean and professor emeritus at the University of Mississippi School of Medicine and chair of the 2025 guideline writing committee, described the shift as a matter of using better data. The PREVENT equations draw on more contemporary datasets and fold in kidney and metabolic disease — conditions tightly linked to blood pressure — in ways the older models did not. The result, he argued, is a more comprehensive and reliable prediction for each patient.
Sadiya S. Khan, the Magerstadt Professor of Cardiovascular Epidemiology at Northwestern's Feinberg School of Medicine and chair of the scientific statement writing group, framed the tool's significance in terms of what it makes possible. PREVENT™ is the first risk instrument to combine cardiovascular, kidney, and metabolic health data in a single calculation aimed at primary prevention. The goal, she said, is not just to count risk but to act on it — to tailor care so that patients can live longer, healthier lives. Crucially, she emphasized that the risk posed by high blood pressure is not fixed. It can be changed.
The scientific statement stops short of making direct treatment recommendations — that is the role of the clinical guidelines — but it lays out the evidence base, explains the rationale behind the 7.5 percent threshold, and offers practical guidance for clinicians trying to weave PREVENT™ into routine care. The writing group also identifies areas where more research is needed.
For clinicians, the next practical challenge is integration: getting the PREVENT™ calculator embedded into electronic health record systems so that risk scoring becomes a routine part of every hypertension visit rather than an extra step. That infrastructure question will likely determine how quickly the guideline's promise translates into changed outcomes at the bedside.
Citas Notables
The PREVENT equations are more comprehensive and will give a stronger and more accurate risk prediction for our patients, allowing us to personalize care.— Daniel W. Jones, M.D., chair of the 2025 High Blood Pressure Guideline writing committee, University of Mississippi School of Medicine
The most important message for clinicians and patients is that risk from high blood pressure is modifiable — the goal is to tailor preventive care so patients can achieve longer, healthier lives.— Sadiya S. Khan, M.D., chair of the scientific statement writing group, Northwestern's Feinberg School of Medicine
La Conversación del Hearth Otra perspectiva de la historia
What's actually new here — haven't doctors always tried to weigh risk before prescribing blood pressure medication?
They have, but the tools they used were narrower. The old model estimated only one type of cardiovascular risk and drew on older, less diverse data. PREVENT™ casts a wider net and reflects who Americans actually are today.
What does it mean in practice that the tool includes a zip code-based social deprivation index?
It means two patients with identical blood pressure readings might get different risk scores if one lives in a neighborhood with limited healthcare access, poor food environments, or chronic stress. The biology doesn't happen in a vacuum.
The 7.5 percent threshold — where does that number come from?
It's the point at which the evidence shows medication adds meaningful benefit over lifestyle changes alone. Below that line, the risk of side effects and the burden of a daily pill may outweigh the gain. Above it, the math shifts.
There was concern the new guideline would leave more people unmedicated. Has that been resolved?
The statement addresses it head-on. The total number of people recommended for medication is roughly the same as under the 2017 guideline. The difference is that the new tool is better at identifying which individuals those should be.
What does it mean that PREVENT™ includes kidney and metabolic health?
Kidney function and metabolic conditions like diabetes aren't just comorbidities — they interact directly with blood pressure and cardiovascular risk. Leaving them out of the calculation was always an incomplete picture.
Is this statement telling doctors what to do, or just summarizing the evidence?
It's the latter. Scientific statements map the terrain; guidelines issue the directions. This one explains why the 2025 guideline made the choices it did and points toward where the research still has gaps.
What's the thing that has to happen next for this to actually change patient care?
The calculator needs to live inside the electronic health record — one click, not a separate website. Until that's routine, the best tool in the world sits unused during a twelve-minute appointment.